NCT03127137View on ClinicalTrials.gov

CESI With Low Dose Lidocaine and Transient Weakness

PHASE4CompletedINTERVENTIONAL
Enrollment

123

Participants

Timeline

Start Date

August 1, 2018

Primary Completion Date

June 6, 2019

Study Completion Date

June 15, 2019

Conditions
Cervical RadiculitisPain
Interventions
DRUG

Experimental Group 1 triamcinolone and lidocaine

Experimental Group 1 will receive Interlaminar cervical ESI at the C7-T1 level with triamcinolone 80 mg + 2 mL 1% lidocaine (total volume 4 cc)

DRUG

Experimental Group 2 triamcinolone and saline

Interlaminar cervical ESI at the C7-T1 level with triamcinolone 80 mg + 2 mL preservative saline (total volume 4 cc)

Trial Locations (1)

60611

Northwestern Memorial Hospital, Chicago

All Listed Sponsors
lead

Northwestern University

OTHER

NCT03127137 - CESI With Low Dose Lidocaine and Transient Weakness | Biotech Hunter | Biotech Hunter